Recently, many therapeutic agents for prostate cancer have been approved that target the
androgen receptor and/or the prostate tumor microenvironment. Each of these therapies has …

Prostate cancer is the most common cause of cancer in men, with 137.9 new cases per
100,000 men per year. The overall 5-year survival rate for prostate cancer is very high. Up to …

Prostate cancer (PCa) is one of the most commonly diagnosed malignancies and among the
leading causes of cancer-related death worldwide. It is a highly heterogeneous disease …

Molecular markers have the potential to serve not only as prognostic factors but may be
targets for new therapeutic strategies and predictors of response in a range of cancers …

Advances in our understanding of the mechanisms driving castration-resistant prostate
cancer have promoted the development of several new drugs including androgen receptor …

Prostate cancer remains one of the leading causes of cancer death in men worldwide. In the
past decade, several new treatments for advanced prostate cancer have been approved …

While localised prostate cancer can be cured by local treatment,'high-risk'prostate cancer
often progresses to castration resistant disease and remains incurable with a dismal …

Prostate cancer progression involves activation of signaling pathways controlling cell
proliferation, apoptosis, anoikis, angiogenesis and metastasis. The current PSA-based test …

Over the past several years, analyses of data from high-throughput studies have elucidated
many fundamental insights into prostate cancer biology. These insights include the …

In the past decade, multi-national and multi-center efforts were launched to sequence
prostate cancer genomes, transcriptomes, and epigenomes with the aim of discovering the …